Clinical Trials
6
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:2
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (66.7%)Phase 1
2 (33.3%)Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
Phase 2
Not yet recruiting
- Conditions
- Malignant Melanoma With MetastasisMalignant MelanomaMalignant Melanoma Stage IIIcMalignant Melanoma Stage IV
- Interventions
- Drug: Chemotherapy Prior to RAPA-201 Therapy
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Rapa Therapeutics LLC
- Target Recruit Count
- 65
- Registration Number
- NCT06708455
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
RAPA-501 Therapy of ALS Expanded Access Protocol
Phase 2
- Conditions
- Amyotrophic Lateral Sclerosis
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Rapa Therapeutics LLC
- Target Recruit Count
- 40
- Registration Number
- NCT06169176
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Mayo Clinic Hospital Phoenix, Scottsdale, Arizona, United States
🇺🇸University of California Irvine Health, Irvine, California, United States
RAPA-201 Therapy of Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid TumorSmall Cell and Non-small Cell Lung CancerHead and Neck CancerSquamous Cell Carcinoma of Oral CavitySquamous Cell Carcinoma of LarynxSquamous Cell Carcinoma of NasopharynxSquamous Cell Carcinoma of Other Specified Sites of SkinMalignant MelanomaEsophageal Squamous Cell Carcinoma
- Interventions
- Drug: Chemotherapy Prior to RAPA-201 Therapy
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Rapa Therapeutics LLC
- Target Recruit Count
- 37
- Registration Number
- NCT05144698
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
RAPA-501-Allo Therapy of COVID-19-ARDS
Phase 1
Terminated
- Conditions
- Severe COVID-19 Disease
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Rapa Therapeutics LLC
- Target Recruit Count
- 1
- Registration Number
- NCT04482699
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
RAPA-501 Therapy for ALS
Phase 2
Recruiting
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Biological: RAPA-501 Autologous T stem cells
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Rapa Therapeutics LLC
- Target Recruit Count
- 41
- Registration Number
- NCT04220190
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
- Prev
- 1
- 2
- Next
News
No news found